<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02088645</url>
  </required_header>
  <id_info>
    <org_study_id>KFS-3170-02-2013</org_study_id>
    <nct_id>NCT02088645</nct_id>
  </id_info>
  <brief_title>177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.</brief_title>
  <acronym>Lumed</acronym>
  <official_title>177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Krebsforschung Schweiz, Bern, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paul Scherrer Institut, Villigen, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of
      patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin
      analogon, binding to cholecystokinin-2 receptors. This receptors show an overexpression on
      more than 90 % of medullary thyroid carcinomas.

      In the pilot (phase 0) study we will correlate the tumour detection rate with the surgery and
      histology (proof of concept study). Furthermore, kidney protection and dosimetry studies will
      be performed in order to determine the kidney protection protocol and starting activity for
      the dose escalation study in the following, dose escalation (phase I) study. In the phase I
      study we will determinate the maximum tolerated dose of 177Lu-PP-F11N in patients with MTC.
      Furthermore, correlation with tumour radiation dose and treatment response as well as organ
      radiation doses and maximal tolerated dose will be performed in order to allow prospective
      individual patient tailored therapy planning.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 0: Scintigraphic visualisation rate</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Phase 0 study: Evaluation of the scintigraphic visualisation of metastases after test injection, verification of 177Lu-PP-F11N uptake in metastases and correlation with surgery/histology if possible (poof of principle study).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: Maximum tolerated dose</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>Phase I study: Determination of the maximum tolerated dose (MTD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 0: Tumour-to-kidney radiation doses</measure>
    <time_frame>8 and 16 weeks</time_frame>
    <description>Evaluation of the kidney radiation dose and the tumour-to-kidney radiation dose ratios with and without kidney protection (Physiogel). Composite measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 0: Radiation doses</measure>
    <time_frame>8 and 16 weeks</time_frame>
    <description>Calculation of tumour and organ radiation doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 0: In vivo stability</measure>
    <time_frame>8 and 16 weeks</time_frame>
    <description>Evaluation of in vivo stability of 177Lu-PP-F11N.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 0: Metabolites</measure>
    <time_frame>8 and 16 weeks</time_frame>
    <description>Measurement of the metabolites of 177Lu-PP-F11N with and without Physiogel infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Side reactions</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
    <description>Evaluation of side reactions of 177Lu-PP-F11N.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Biochemical response</measure>
    <time_frame>For the duration of 24 months.</time_frame>
    <description>Evaluation of biochemical response (decrease of calcitonin and calculation of calcitonin doubling time).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Morphological response</measure>
    <time_frame>0, 3 and 12 months</time_frame>
    <description>Evaluation of morphological therapy response (RECIST criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Tumour detection rate</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
    <description>Determination of the tumour detection rate and correlation with surgery/histology, if possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Organ radiation doses</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
    <description>Calculation of organ radiation doses after therapy and correlation with the determined MTD (composite measure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Determination of overall survival of patients after therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: In vivo stability</measure>
    <time_frame>8, 16 und 24 weeks</time_frame>
    <description>Evaluation of in vivo stability of 177Lu-PP-F11N.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Metabolites</measure>
    <time_frame>8, 16 and 24 weeks</time_frame>
    <description>Measurement of the metabolites of 177Lu-PP-F11N.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Thyroid Cancer, Medullary</condition>
  <arm_group>
    <arm_group_label>Phase 0: One arm; Phase I: One arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 0: 6 patients, intravenous application of 2 x 1 gigabequerel (GBq) 177Lu-PP-F11N with and without Physiogel (crossover)
Phase I: expected 12 - 18 patients, intravenous application of 3 x max. 15 GBq 177Lu-PP-F11N (increasing activity in 1 GBq steps in groups of three patients). All patients with or without Physiogel, depending on the results of the phase 0 study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-PP-F11N</intervention_name>
    <arm_group_label>Phase 0: One arm; Phase I: One arm</arm_group_label>
    <other_name>Minigastrin analogue</other_name>
    <other_name>Gastrin analogue</other_name>
    <other_name>Cholecystokinin-2 receptor ligand</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Phase 0 study

          -  Advanced MTC with elevated levels of calcitonin (&gt; 100 pg/ml) and/or
             calcitonin-doubling time &lt; 24 months before or after total thyroidectomy - Age &gt; 18
             years

          -  Informed consent

        Phase I study

          -  Diagnostic, contrast medium enhanced CT scan neck/thorax/abdomen, not older than 4
             weeks

          -  Advanced MTC with elevated levels of calcitonin (&gt; 100 pg/ml) and/or
             calcitonin-doubling time &lt; 24 months before or after total thyroidectomy- Age &gt; 18
             Years

          -  Informed consent

          -  Curative surgical therapy not possible

        Exclusion Criteria:

        Phase 0 study

          -  Medication with Vandetanib 3 weeks before the study and during the study

          -  Renal failure (calculated glomerular filtration rate (GFR) &lt; 60 ml/min per 1.73 m2
             body surface).

          -  Bone marrow failure (thrombocytes &lt; 70 000/μl, leucocytes &lt; 2 500/μl, hemoglobin &lt; 8
             g/dl).

          -  Pregnancy and breast feeding

          -  Knows allergic reaction on Physiogel or other gelatine products

          -  Known, serious side reaction in the case of a former application of pentagastrin

          -  Active, second malignancy oder remission after second malignancy &lt; 5 years

        Phase I study

          -  Medication with Vandetanib 3 weeks before the study and during the study

          -  Renal failure (calculated GFR &lt; 70 ml/min per 1.73 m2 body surface).

          -  Bone marrow failure (thrombocytes &lt; 100 000/μl, leucocytes &lt; 3 000/μl, hemoglobin &lt; 10
             g/dl).

          -  Pregnancy and breast feeding

          -  Known allergic reaction on Physiogel or other gelatine products

          -  Known, serious side reaction in the case of a former application of pentagastrin

          -  Active, second malignancy oder remission after second malignancy &lt; 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christof Rottenburger, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Damian Wild, Prof Dr Dr</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christof Rottenburger, Dr. med.</last_name>
    <phone>0041613286551</phone>
    <email>Christof.Rottenburger@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Damian Wild, Prof Dr Dr</last_name>
    <phone>0041613286683</phone>
    <email>damian.wild@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Basel, Clinic for radiology and nuclear medicine</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christof Rottenburger, Dr. med.</last_name>
      <phone>0041613286551</phone>
      <email>christof.rottenburger@ubs.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Calcitonin</keyword>
  <keyword>Medullary thyroid carcinoma</keyword>
  <keyword>Peptide receptor radionuclide therapy</keyword>
  <keyword>Gastrin</keyword>
  <keyword>Cholecystokinin-2 receptor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrins</mesh_term>
    <mesh_term>Cholecystokinin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

